Ectopic Acsl6 Overexpression Partially Improves Isoproterenol-Induced Cardiac Hypertrophy In Vivo and Cardiomyocyte Hypertrophy In Vitro

Abstract

The increase in cardiac myocyte size is a critical issue in cardiac hypertrophy development. In this study, 61 differentially expressed genes between hypertrophic rats and normal controls were enriched in the positive modulation of fatty acid uptake, fatty acid metabolism and degradation, cardiac conduction, and the oxidation of carbohydrates and other processes. Acsl6 was significantly downregulated in hypertrophic rat and mouse hearts according to online data. Based on the experimental data, Acsl6 was underexpressed in ISO-induced cardiac hypertrophy mouse model and isoproterenol (ISO)-induced cardiomyocyte hypertrophy cell model. In vivo, Acsl6 overexpression partially attenuated ISO-induced increases in the cross-sectional area and cardiac hypertrophy, elevated hypertrophic markers, and caused impairment of cardiac function. In vitro, Acsl6 overexpression partially attenuated ISOinduced cardiomyocyte hypertrophy and increased hypertrophic markers. Conclusively, Ascl6 is downregulated in ISO-induced cardiac hypertrophy mouse model and ISO-induced cardiomyocyte hypertrophy cell model. Acsl6 overexpression could partially improve cardiac hypertrophy in vivo and cardiomyocyte hypertrophy in vitro, possibly through the regulation of HIF-1a/Hippo pathway.

Identification of key genes and signaling pathway in the pathogenesis of Huntington's disease via bioinformatics and next generation sequencing data analysis

“…Altered expression of FA2H [441], DSCAM (DS cell adhesion molecule) [442], OLIG2 [328], PCDH15 [443], GRID2 [424], CTTNBP2 [444], AFF2 [445], SYNE2 [446] and EGFR (epidermal growth factor receptor) [447] are associated with autism spectrum disorder. FA2H [111], SERPINA1 [448], HOXB9 [113], TGM2 [449], LRRK2 [450], ROS1 [451], CFC1 [452], GDF3 [453], TF (transferrin) [121], RXFP1 [454], RELN (reelin) [455], HTR2C [456], MYL7 [457], DYSF (dysferlin) [458], GJA5 [459], IRX1 [460], TLL1 [461], SUCNR1 [462], KERA (keratocan) [463], TFAP2B [464], HOXA5 [465], ACSL6 [466], DSCAM (DS cell adhesion molecule) [467], MSR1 [468], REN (renin) [64], VEGFC (vascular endothelial growth factor C) [469], TLR2 [470], PCSK2 [471], FGF12 [472], SLC22A3 [142], HSPB7 [473], CSRP3 [474], KLRD1 [475], PTPRO (protein tyrosine phosphatase receptor type O) [476], IL7R [477], CUX2 [478], ACAN (aggrecan) [479], SHH (sonic hedgehog signaling molecule) [480], MEOX1 [481], AGTR1 [482], VTN (vitronectin) [483], SIRT2 [79], RBP4 [484], IL2RG [485], EPAS1 [486], CDH13 [487], TRPC6 [488], MMP3 [261], PCDHGA3 [489], FGF19 [490], TBX18 [491], HLA-DRB1 [492]. CD74 [493], VWF (von Willebrand factor) [267], MTTP (microsomal triglyceride transfer protein) [494], ANGPT2 [184], AKR1C3 [495], NEDD4L [496], CASP1 [497], LDB2 [498], CHRNA5 [499], CCND2 [500], BRCA2 [97], ZBTB20 […”